PMU-Autor/inn/en
Bertsch ThomasAbstract
The assessment of S-100B in acute neurological disorders such as global hypoxia, ischaemic or haemorrhagic stroke and traumatic brain injury reflects severity of symptoms and outcome. However, the temporal profile of S-100B release depends on topography, intensity and pathophysiology of the damage e.g. immediate release after traumatic brain injury following the acute destruction of neuronal tissue or delayed release after ischaemic stroke in which gradual breakdown of the blood-brain barrier plays a crucial role. In chronic brain diseases, knowledge about the clinical value of quantification of S-100B is scarce and further evaluations are needed. This review considers both conditions for S-100B measurement and illustrates advantages and limitations in comparison with clinical and neuroimaging data.
Useful keywords (using NLM MeSH Indexing)
Animals
Biomarkers/blood*
Blood-Brain Barrier/metabolism
Blood-Brain Barrier/pathology
Brain Injuries/blood
Brain Injuries/diagnosis*
Brain Ischemia/blood
Brain Ischemia/diagnosis
Cell Hypoxia/physiology
Cerebral Hemorrhage/blood
Cerebral Hemorrhage/diagnosis
Cerebrovascular Disorders/blood
Cerebrovascular Disorders/diagnosis*
Humans
Prognosis
S100 Proteins/blood*
Trauma Severity Indices
Find related publications in this database (Keywords)
S-100B